Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan’s Eisai Gets U.S. FDA Approvals For Two Drugs

This article was originally published in PharmAsia News

Executive Summary

The U.S. FDA has approved Eisai's Aloxi (palonosetron hydrochloride) anti-nausea drug for use in preventing post-surgery vomiting, and its Vasolan (verapamil) for treating atrial fibrillation. The Aloxi approval is for a new indication for the drug, approved five years ago for treating nausea caused by chemotherapy. Eisai anticipates up to $600 million total sales for the drug beginning in 2011. The Vasolan approval also is an additional indication, the drug having been approved earlier for treating coronary heart disease. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068054

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel